Latest News and Updates | Cantargia

* (R) = Regulatory press releases

Oct 1, 2018

(R) Cantargia obtains patent in USA for the antibody CAN03

Sep 19, 2018

(R) Cantargia publishes prospectus in connection with the list change to Nasdaq Stockholm’s main market

Sep 19, 2018

(R) Cantargia obtains patent approval for the antibody CAN04 (nidanilimab) in Japan

Sep 13, 2018

(R) Cantargia has been approved for listing on the main market of Nasdaq Stockholm

Aug 21, 2018

(R) Cantargia publishes half year report

Aug 13, 2018

(R) Cantargia presents update on the CANFOUR clinical trial and phase IIa preparations

Aug 1, 2018

(R) Cantargia obtains patent approval for the antibody CAN04 (nidanilimab) in China

Jul 13, 2018

(R) Cantargia approved for listing on Nasdaq Stockholm First North Premier as part of the process towards Nasdaq Stockholm's main market

Jul 11, 2018

(R) Cantargia receives Intention to grant notification from EPO for expanded patent protection in treatment of solid tumours

Jun 26, 2018

(R) Cantargia announces pre-clinical results showing positive effects of CAN04 combined with approved cancer therapies

<< Newer press releases Older press releases >>

Cantargia Q1 2025 interview with Interim CEO Damian Marron - 2025-05-14

Redeye

Redeye interviews Interim CEO Damian Marron - 2024-12-10

Redeye

Interview with CEO VD Göran Forsberg (In Swedish) - 2024-12-10

BioStock

Redeye interviews CEO Göran Forsberg about the expansion of CAN10's phase 1 study (In Swedish) - 2024-12-02

Redeye

Interview with CEO Göran Forsberg about the expansion of CAN10's phase 1 study and rights issue (In Swedish) - 2024-12-02

Biostock

Interview with CEO Göran Forsberg about the latest results from the phase 1 study of CAN10 and the development of nadunolimab in pancreatic cancer - 2024-10-14

Redeye

Interview with CEO Göran Forsberg about new results from the phase 1 study of CAN10 - 2024-08-12

Redeye

Interview with CEO Göran Forsberg regarding new results in pancreatic cancer - 2024-06-28

Redeye

Interview with CEO Göran Forsberg about the new neuropathy results with nadunolimab in pancreatic cancer that will be presented at ASCO. (In Swedish) - 2024-05-24

Redeye

CEO Göran Forsberg interviewed on new results with CAN10 and external validation of IL-1 blockade during inflammatory disease. (In Swedish) - 2023-03-15

Redeye

Redeye interviews CEO Göran Forsberg about new results on nadunolimab and alleviation of neuropathy during chemotherapy. (In Swedish) - 2024-02-14

Redeye

COO Liselotte Larsson presents at Redeye Life Science Day - 2023-11-23

Redeye

CEO Göran Forsberg comments on the quarterly report (In Swedish) - 2023-11-10

Di TV

Interview with CEO Göran Forsberg about the directed share issue (In Swedish) - 2023-10-31

Redeye

Interview with CEO Göran Forsberg about new TRIFOUR results (In Swedish) - 2023-10-23

Redeye

CEO Interview, New results for nadunolimab monotherapy and IL1RAP as a biomarker presented at AARC (In Swedish) - 2023-10-02

Redeye

CEO Interview, about expanded clinical pipeline and start of treatment in CAN10, for autoimmune diseases. (In Swedish) - 2023-09-05

Redeye

CEO interview, about the new readout from trials in non-small cell lung cancer - 2023-05-31

Redeye

CEO interview, Interim efficacy results nadunolimab (In Swedish) - 2023-05-31

Västra Hamnen Corporate Finance

CEO interview, Promising interim efficacy results for nadunolimab in lung cancer - 2023-05-26

Di TV

Cantargia presents updated interim results - 2023-05-26

Di TV

CEO interview, New clinical development strategy for nadunolimab in pancreatic cancer - 2023-05-17

Redeye

CEO interview, Positive results published at the AARC-conference 2023 - 2023-04-19

Redeye

CEO interview, New positive research results (In Swedish) - 2023-03-15

DiTV

CEO interview, CANFOUR new Biomarker data (In Swedish)- 2023-03-15

Redeye

CEO interview, TRIFOUR result (In Swedish)- 2023-02-23

Redeye

CEO interview, Redeye Life Science Day (In Swedish) - 2022-11-24

Redeye

CEO interview, Edison - 2022-06-24

Edison

CEO interview, Rights issue, Redeye (In Swedish) - 2022-06-22

Redeye

CEO interview, Edison - 2022-03-16

Edison

Panel discussion – Business development

Redeye

CEO interview, Redeye, (In Swedish) - 2021-08-31

Redeye

CEO interview, Di TV (In Swedish) - 2021-05-26

Di TV

CEO presentation AGM (In Swedish) - 2021-05-26

Bio Stock

CEO interview, Redeye, (In Swedish) - 2021-05-24

Redeye

CEO interview, Redeye, (In Swedish) - 2021-05-11

Redeye

Interview with CEO Göran Forsberg and CMO Ignacio Garcia-Ribas, Pareto - 2021-03-26

Pareto Securities

CEO interview, Edison - 2021-03-15

Edison

CEO interview, Redeye, (In Swedish) - 2021-03-09

Redeye

Cantargia in a panel discussion on how to build a successful biotech company (In Swedish) - 2021-01-27

Aktiespararna

CEO interview, Edison Open House - 2021-01-26

Edison

CEO interview, direct share issue, Redeye (In Swedish) - 2020-12-16

Redeye

CEO interview, direct share issue, Di TV (In Swedish) - 2020-12-16

Di TV

CEO interview, EFN (In Swedish) - 2020-10-16

EFN

CEO interview, Penser Bank Cancer Research Day (In Swedish) - 2020-10-07

Penser Bank

Article about Cantargias antibody based cancer treatment with multiple functions 2019-10-31

Affärstidningen Näringsliv

Presentation at ASCO 2019, follow up articles and interviews - 2019-07-02

ASCO

Cantargia interview at EFN after ASCO - 2019-06-17

EFN

CEO interview, Edison, London - 2019-02-26

Edison TV

CEO interview, EFN, Lund (In Swedish) - 2018-11-22

EFN

Interview around CAN04 clinical results, Redeye, Stockholm (In Swedish) - 2018-10-23

Redeye

Listing ceremony for Cantargia on Nasdaq Stockholm Main Market - 2018-09-25

Nasdaq

CEO interview in connection with listing Nasdaq Stockholm (Small Cap), EFN, Stockholm (In Swedish) - 2018-09-25

EFN

CEO interview in connection with listing Nasdaq Stockholm (Small Cap), Ditv, Stockholm (In Swedish) - 2018-09-25

Di

CEO interview, Redeye, Stockholm (In Swedish) 2018-09-06

Redeye

CEO interview, BioStock Live, Stockholm (In Swedish) -2018-08-29

Direkt Studios

Småbolagspanelen: Om framtidens cancerbehandlingar, Småbolagsdagen, Stockholm (in Swedish) 2018-06-11

Aktiespararna

CEO interview BioStock Live, Stockholm (In Swedish) -2018-03-20

Direkt Studios

CEO-interview 2017-12-12

Aktiespararna

Interview with Cantargia's CEO Göran Forsberg after the presentation at BioStock Live i Stockholm - 2017-12-04

Direkt Studios

CEO interview - 2017-11-29

Finwire.tv

Video, interview Göran Forsberg, President Cantargia, Sedermera-dagen, Lund - 2016-03-16

Finwire.tv